Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Prior treatment

• Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;
• Previously suffered from myocardial infarction or received coronary artery bypass grafting;
• Patients with concomitant cardiomyopathy or valve disease;
• Currently receiving immunosuppressive therapy;

Other illness

• History of severe liver dysfunction;
• Concurrent severe infections, or liver/gallbladder obstruction, or history of malignant tumors;
• Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations;

Lab values

• History of severe renal failure, estimated glomerular filtration rate (eGFR) \< 30ml/min;

Other

• Pregnant or potentially pregnant and breastfeeding women;
• Without obtaining written informed consent.
• Patients with hemodynamic instability.

• Ages above 18;
• Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial.
• Meet the diagnostic criteria for STEMI, the diagnostic criteria includes:
  • Clinical symptoms: ischemic chest pain lasting for over 30 minites;
  • Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);
  • ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG;
• Emergency coronary angiography and revascularization should be performed;
• Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization.